ライフサイエンスコーパス: human papilloma virus

1 vaccines are available against rotavirus and human papilloma virus.

2 -1, hepatitis B virus, hepatitis C virus and human papilloma virus.

3 and immortalized with the E6 and E7 genes of human papilloma virus.

4 no acids 85-115 of the E4 protein of type 75 human papilloma virus.

5 ent pathway since ME180 is infected with the human papilloma virus.

6 erminal end of the E6 protein from high-risk Human Papilloma Virus.

7 en identified as an important target for the Human Papilloma Virus.

8 c strategies against oncogenesis mediated by human papilloma virus.

9 an increasing percentage are associated with human papilloma virus.

10 ions, such as the vaccines for influenza and human papilloma virus.

11 al virus, adeno-associated virus type 2, and human papilloma virus.

12 ely due to elimination of foreskin harboring human papilloma virus.

13 lloma virus 16 copies/cell, and SiHa, 1 to 2 human papilloma virus 16 copies/cell) and two negative c

14 known viral gene content (CaSki, 200 to 600 human papilloma virus 16 copies/cell, and SiHa, 1 to 2 h

15 HPECs are immortalized using human papilloma virus 16 E6 and/or E7 as molecular tools

16 enes, including the SV40 large T antigen and human papilloma virus 16 E6-antigen.

17 Expression of the human papilloma virus 16 E7 protein (which inactivates a

18 cell-cycle checkpoints (for example, E7 from human papilloma virus 16, and cyclin D1), deregulate Myc

19 Human papilloma virus-16 (HPV-16) associated oropharynge

20 (rLm) strains were produced that secrete the human papilloma virus-16 (HPV-16) E7 protein expressed i

21 sduced with a retroviral vector encoding the human papilloma virus 18 E6 gene, which inactivates endo

22 on of T-cell chemotaxis in a model of stable human papilloma virus-18 infection.

23 Two capsid virus-like particles, human papilloma virus (55 nm, approximately 20,000 kDa)

24 ive effect of Prdx6, which was observed in a human papilloma virus 8-induced and a chemically induced

25 Infection of influenza or human papilloma virus 9-mer peptide-pulsed DCs from diff

26 in families and as SPCs are associated with human papilloma virus and smoking related cancers.

27 to evaluate temporal trends and the role of human papilloma virus and to determine the academic trai

28 Two therapeutic vaccine candidates against human papilloma viruses and melanoma have been developed

29 oradiation (CRT), associated with anogenital human papilloma virus, and often appears in HIV infectio

30 High-risk human papilloma viruses are known to be associated with

31 ith head and neck squamous cell cancer, both human papilloma virus-associated and human papilloma vir

32 are of renewed importance in the context of human papilloma virus-associated disease, in which young

33 ng HPV-16 E7 for the treatment of metastatic human papilloma virus-associated epithelial cancers (NCT

34 enhances the effect of radiation therapy in human papilloma virus-associated oropharyngeal SCC, we h

35 better prognosis in unselected patients with human papilloma virus-associated oropharyngeal squamous

36 enhances the effect of radiation therapy in human papilloma virus-associated oropharyngeal squamous

37 3G and induces G-to-A or C-to-T mutations in human papilloma virus cervical cell lines and genital wa

38 's and NBF solutions were also evaluated for human papilloma virus content using DNA ISH.

39 sociated protein (E6AP; as classified in the human papilloma virus context) is an E3 ligase that has

40 A decamer d(GACCGCGGTC), containing half the human papilloma virus E2 binding site, has been solved f

41 vate transcription of the genes encoding the human papilloma virus E6 and E7 proteins and is over-exp

42 induced by wt-p53 but not by mutant p53, and human papilloma virus E6 inhibited the p53-dependent act

43 Inactivation of p53, by the human papilloma virus E6 oncoprotein, does not prevent P

44 erpart, ubiquitinates p53 in the presence of human papilloma virus E6 protein, while Nedd-4 does not.

45 and can be abrogated by the co-expression of human papilloma virus E6 protein.

46 Elimination of p53 by expression of human papilloma virus E6 resulted in an inability to dow

47 The human papilloma virus E6-associated protein (E6AP) funct

48 inhibits tumour growth in the B16F10-OVA and human papilloma virus-E6/E7 tumour models in mice.

49 wth inhibition in melanoma, colon cancer and human papilloma virus-E6/E7 tumour models.

50 frequently inactivated by the binding of the human papilloma virus E7 oncoprotein in cervical cancer.

51 apamycin affects the antitumor efficacy of a human papilloma virus E7 peptide vaccine (CyaA-E7) capab

52 eter for the growthpromoting activity of the human papilloma virus E7 protein.

53 ormed mouse embryonic fibroblasts but not in human papilloma virus-E7 expressing fibroblasts.

54 tes, the only cell type directly infected by human papilloma virus, express functional gammac and its

55 Human papilloma virus has shown differential levels of p

56 y to test women for the causative agent, the human papilloma virus, has emerged as a potential screen

57 Vaccines against rotavirus and human papilloma virus have entered clinical use.

58 ficiency virus, human T cell leukemia virus, human papilloma virus, hepatitis B and C viruses, herpes

59 like the other group 1 carcinogens including human papilloma virus, hepatitis C virus, and Helicobact

60 like the other Group 1 carcinogens including human papilloma virus, hepatitis C virus, and Helicobact

61 Risk factors, including human papilloma virus, HIV, and the practice of circumci

62 ic viral diseases such as hepatitis B virus, human papilloma virus, HIV, or chronic hepatitis C.

63 cer have focused on its association with the human papilloma virus; however, there have also been sev

64 an endogenous retrovirus (HERV-W), HHV2, and human papilloma virus (HPV) (weakest association).

65 ples were collected from women with healthy, human papilloma virus (HPV) +/- cervical intraepithelial

66 ating a peptide from the clinically-relevant human papilloma virus (HPV) 16 E7 oncoprotein induces cy

67 Identifying human papilloma virus (HPV) and human immunodeficiency v

68 Molecular classification on the basis of human papilloma virus (HPV) and tumor protein 53 (p53) s

69 n patients whose lesions tested positive for human papilloma virus (HPV) and/or who endorsed a histor

70 High-risk types of human papilloma virus (HPV) are increasingly associated

71 High-risk subtypes of the human papilloma virus (HPV) are the cause of the disease

72 Human papilloma virus (HPV) causes focal infections of e

73 se was performed in those with genitourinary human papilloma virus (HPV) disease versus those without

74 treated with vemurafenib for the presence of human papilloma virus (HPV) DNA and identified 13% to be

75 The prevalence of human papilloma virus (HPV) DNA in different histologica

76 We assayed for the presence of human papilloma virus (HPV) DNA in serum and/or peripher

77 The E6 and E7 oncoproteins of human papilloma virus (HPV) drive the majority of genita

78 mor suppressor pathways are disrupted by the human papilloma virus (HPV) E6 and E7 oncoproteins, beca

79 inocytes and identified protein partners for human papilloma virus (HPV) E6 proteins.

80 Loss of p16(INK4A) or the presence of human papilloma virus (HPV) E6/E7 oncogene products not

81 ies over the past decades owing to increased human papilloma virus (HPV) exposure.

82 Recently, the human papilloma virus (HPV) has been implicated in the r

83 viruses (HHVs), human polyomavirus JCV, and human papilloma virus (HPV) have been implicated in brai

84 n cervical cancer has elucidated the role of human papilloma virus (HPV) in the pathogenesis of cervi

85 carcinomas (OPSCC) that are associated with human papilloma virus (HPV) infection carry a more favor

86 ve implicated estrogenic exposure as well as human papilloma virus (HPV) infection in cervical carcin

87 carcinoma (HNSCC) associated with high-risk human papilloma virus (HPV) infection is a growing clini

88 s was confirmed by a study on the effects of human papilloma virus (HPV) infection to the EC's respon

89 In a longitudinal study of human papilloma virus (HPV) infection, female adolescent

90 gnancies that have seen growing burdens with human papilloma virus (HPV) infection.

91 As persistent human papilloma virus (HPV) infections are a key causati

92 In a third of PSC cases, presence of human papilloma virus (HPV) is found.

93 man leukocyte antigen-A*02:01 presenting the human papilloma virus (HPV) peptide HPV16 E7(11-19), 4-1

94 maller case-control datasets (samples either Human Papilloma Virus (HPV) positive or negative).

95 In cervical cancer cells, human papilloma virus (HPV) protein E7 binds to Rb, rele

96 In women, naturally induced anti-human papilloma virus (HPV) serum antibodies are a likel

97 E6/E7 oncogenes of high-risk human papilloma virus (HPV) subtypes are essential for t

98 ase of the aerodigestive tract caused by the Human Papilloma Virus (HPV) that manifests as profoundly

99 Specific human papilloma virus (HPV) types appear to be necessary

100 ssociated with approximately 13 carcinogenic human papilloma virus (HPV) types in a broader group tha

101 Despite preventive human papilloma virus (HPV) vaccination efforts, cervica

102 Public trust in the human papilloma virus (HPV) vaccination programme has be

103 Most cervical cancers are caused by human papilloma virus (HPV), and HPV circulating tumor D

104 virus 4 (HHV4), human herpes virus 5 (HHV5), human papilloma virus (HPV), human JC polyoma virus (JCV

105 es discussed include influenza, hepatitis B, human papilloma virus (HPV), human T-cell lymphotrophic

106 itis B virus (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), human T-cell lymphotropic v

107 e than 99% of cervical cancers are caused by human papilloma virus (HPV), measurement of HPV (HPV tes

108 DNA of human papilloma virus (HPV), the major etiological agent

109 Human papilloma virus (HPV)-16 DNA was hybridized to pro

110 We have shown that the human papilloma virus (HPV)-16 E7 gene is sufficient to

111 or Brn-3a differentially regulates different human papilloma virus (HPV)-16 variants that are associa

112 We study a patient with the human papilloma virus (HPV)-2-driven "tree-man" phenotyp

113 herapies such as immune-checkpoint blockade, human papilloma virus (HPV)-directed vaccines and adopti

114 arison of normal oral epithelial cells and a human papilloma virus (HPV)-immortalized oral epithelial

115 In the TC-1 mouse allograft model of human papilloma virus (HPV)-induced cancer, a single adm

116 Human papilloma virus (HPV)-like particles (VLPs) have b

117 We present a proteogenomic study of 108 human papilloma virus (HPV)-negative head and neck squam

118 regards to radioresistance, particularly of Human Papilloma Virus (HPV)-negative tumors.

119 ma of the vulva is diverse and includes both human papilloma virus (HPV)-positive and HPV-negative pa

120 Purpose The incidence of human papilloma virus (HPV)-positive oropharyngeal cance

121 were particularly higher among patients with human papilloma virus (HPV)-positive tumors.

122 n HIV-positive patients followed closely for human papilloma virus (HPV)-related anal neoplasia after

123 Using 10 images of penises with human papilloma virus (HPV)-related disease, we trained

124 ent tumor induction by pathogenic strains of human papilloma virus (HPV).

125 osure to tobacco, alcohol and infection with human papilloma virus (HPV).

126 cle and transcription of oncogenes, HIV, and human papilloma virus (HPV).

127 ease with solar radiation exposure, HIV, and human papilloma virus (HPV).

128 c cell lines in which p53 was inactivated by human papilloma virus (HPV)16E6 protein or by a dominant

129 prevention and screening recommendations for human papilloma virus (HPV); and appropriate testing for

130 protein (LAMP-1) to the cytoplasmic/nuclear human papilloma virus (HPV-16) E7 antigen, creating a ch

131 ble of controlling tumors induced by type 16 human papilloma virus (HPV-16).

132 arr virus (EBV), hepatitis B virus (HBV) and human papilloma virus (HPV; for example, HPV16 or HPV18)

133 Over the past 20 years, high-risk human papilloma-virus (HPV) infection has been establish

134 their association with high-risk subtypes of human papilloma virus (HPV16 and HPV18).

135 The impact of human papilloma virus (HPV16) E7 proteins and retinoblas

136 High-risk human papilloma viruses (HPVs) have been recognized as i

137 etiological role of infection with high-risk human papilloma viruses (HPVs) in cervical carcinomas is

138 tification of PPIs that discriminate between human papilloma viruses (HPVs) with high and low oncogen

139 ls can be infected by more than 200 types of human papilloma viruses (HPVs), and persistent HPV infec

140 linked to infection with high-risk types of human papilloma viruses (HPVs).

141 ers et al. (2014) demonstrate that high-risk human papilloma viruses (hrHPVs) attenuate the magnitude

142 anced cytokine expression and the absence of human papilloma virus in aggressive tumors.

143 uced cytokine expression and the presence of human papilloma virus in chemoradiation-sensitive basalo

144 RKO cells transfected with the E6 protein of human papilloma virus (inactivating p53).

145 elial tumours induced by 'high-risk' mucosal human papilloma viruses, including human cervical carcin

146 iquitin ligase E6AP (UBE3A) is implicated in human papilloma virus-induced cervical tumorigenesis and

147 s), excess bodyweight (three provinces), and human papilloma virus infection (one province).

148 ntial DNA methylation changes in relation to human papilloma virus infection and age.

149 Cervical cancer is associated with human papilloma virus infection.

150 and is typically associated with anogenital human papilloma virus infection.

151 order comprising susceptibility to cutaneous human papilloma virus infections and associated nonmelan

152 al CIS types suggest that life style related human papilloma virus infections contributed to the obse

153 neages, a long-term risk of severe cutaneous human papilloma virus infections persists, possibly rela

154 Sexual transmission of human papilloma virus is a leading risk factor for cervi

155 , such that loss of p53 through mutation, or human papilloma virus-mediated inhibition, prevents recr

156 The incidence of human papilloma virus-mediated oropharyngeal squamous ce

157 r, both human papilloma virus-associated and human papilloma virus-negative tumors.

158 The human papilloma virus oncogene 16E6 induces telomerase a

159 utations in the pocket and by binding of the human papilloma virus oncoprotein E7.

160 ge T antigen of SV40 virus, by E6 protein of human papilloma virus, or by genetic deletion led to the

161 other organs or any history of herpes virus, human papilloma virus, or human immunodeficiency virus i

162 We selected a murine model of human papilloma virus-positive head and neck cancer base

163 here up-regulated DEK protein levels in both human papilloma virus-positive hyperplastic murine skin

164 Human papilloma virus presence does not seem to be requi

165 ical, mental, and sexual health (including a human papilloma virus programme), an investment of US$4.

166 Inactivation of pocket proteins with human papilloma virus protein E7 partially, but not comp

167 er, although a recent study also showed that human papilloma virus-reactive T cells can induce comple

168 r were selected for this purpose, a model of human papilloma virus-related head and neck cancer and a

169 For this purpose, we used a murine model of human papilloma virus-related head and neck cancer paire

170 Funding for human papilloma virus-related projects gradually rose, f

171 activity against herpes simplex virus (HSV), human papilloma virus, respiratory syncytial virus (RSV)

172 with the E6 and E7 transforming proteins of human papilloma virus serotype 16 was necessary to estab

173 ch as human immunodeficiency virus (HIV) and human papilloma virus; several cancers, including follic

174 Human papilloma virus status was not found to be associa

175 Despite infection with high-risk human papilloma virus subtypes, which is a major etiolog

176 These guidelines incorporate human papilloma virus testing based on a multicenter tri

177 the appropriate methods of incorporation of human papilloma virus testing into the screening protoco

178 eceptor, and MIS inhibits the growth of both human papilloma virus-transformed and non-human papillom

179 th human papilloma virus-transformed and non-human papilloma virus-transformed cervical cell lines, w

180 of a ternary complex comprising full-length human papilloma virus type 16 (HPV-16) E6, the LxxLL mot

181 that TR2 is able to induce the expression of human papilloma virus type 16 (HPV-16) genes via binding

182 es and is able to activate expression of the human papilloma virus type 16 (HPV-16) upstream regulato

183 E7 is the main transforming protein of human papilloma virus type 16 (HPV16) which is implicate

184 Inhibition of wild-type p53, by either human papilloma virus type 16 E6 or a dominant-negative

185 al parental cultures with viral oncoproteins human papilloma virus type 16 E6/E7 with and without hTE

186 , E7 (which binds pRB), or both E6 and E7 of human papilloma virus type 16.

187 romosome 8q24.21 at which integration of the human papilloma virus type 18 (HPV-18) genome occurred a

188 , v-src, mutant type 5 adenovirus (Ad5), and human papilloma virus type 18.

189 A peptide from human papilloma virus type 40 (HPV 40) containing VHFFR,

190 A PCR screening detected human papilloma virus type 45 DNA (high-risk subtype), a

191 the linkage of CRT to a model tumor antigen, human papilloma virus type-16 (HPV-16) E7, for the devel

192 s enhanced adjuvant activity, such as in the human papilloma virus vaccine Cervarix(R).

193 For example, the human papilloma virus vaccine requires aluminium salt ad

194 ation or the expression of the E6 protein of human papilloma virus, were treated with exogenous ceram

195 ant human virus in urethral swab samples was human papilloma virus, whereas the most abundant bacteri